Safety, efficacy, and pharmacokinetics of XNW28012, a tissue factor antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor (TOP1i) payload, in patients with advanced solid tumors: Results from a phase I/II study.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Fudan University Shanghai Cancer Center, Capital Medical University, Beijing Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, First Affiliated Hospital Zhejiang University, Hunan Cancer Hospital, Binzhou Medical University, Binzhou Medical College Hospital, Chongqing University, Chongqing Cancer Hospital, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Jinan Central Hospital, Shandong First Medical University, Shandong Tumor Hospital
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7162484070
Cites:
Cited by:
Related to: